145 related articles for article (PubMed ID: 18482773)
1. Modulation of IFNAR1 mRNA expression in multiple sclerosis patients.
Serana F; Sottini A; Ghidini C; Zanotti C; Capra R; Cordioli C; Caimi L; Imberti L
J Neuroimmunol; 2008 Jun; 197(1):54-62. PubMed ID: 18482773
[TBL] [Abstract][Full Text] [Related]
2. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
[TBL] [Abstract][Full Text] [Related]
3. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia.
Ito K; Tanaka H; Ito T; Sultana TA; Kyo T; Imanaka F; Ohmoto Y; Kimura A
Eur J Haematol; 2004 Sep; 73(3):191-205. PubMed ID: 15287917
[TBL] [Abstract][Full Text] [Related]
4. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
Leyva L; Fernández O; Fedetz M; Blanco E; Fernández VE; Oliver B; León A; Pinto-Medel MJ; Mayorga C; Guerrero M; Luque G; Alcina A; Matesanz F
J Neuroimmunol; 2005 Jun; 163(1-2):165-71. PubMed ID: 15885318
[TBL] [Abstract][Full Text] [Related]
5. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
McKay F; Schibeci S; Heard R; Stewart G; Booth D
J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
[TBL] [Abstract][Full Text] [Related]
6. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
[TBL] [Abstract][Full Text] [Related]
7. Interferon receptor expression in multiple sclerosis patients.
Oliver B; Mayorga C; Fernández V; Leyva L; León A; Luque G; López JC; Tamayo JA; Pinto-Medel MJ; de Ramon E; Blanco E; Alonso A; Fernández O
J Neuroimmunol; 2007 Feb; 183(1-2):225-31. PubMed ID: 17188754
[TBL] [Abstract][Full Text] [Related]
8. Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.
Aliaga-Gaspar P; Hurtado-Guerrero I; Ciano-Petersen NL; Urbaneja P; Brichette-Mieg I; Reyes V; Rodriguez-Bada JL; Alvarez-Lafuente R; Arroyo R; Quintana E; Ramió-Torrentà L; Alonso A; Leyva L; Fernández O; Oliver-Martos B
Front Immunol; 2021; 12():778204. PubMed ID: 34975865
[TBL] [Abstract][Full Text] [Related]
9. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2.
Marijanovic Z; Ragimbeau J; van der Heyden J; Uzé G; Pellegrini S
Biochem J; 2007 Oct; 407(1):141-51. PubMed ID: 17627610
[TBL] [Abstract][Full Text] [Related]
10. Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis.
Reuss R; Pohle S; Retzlaff K; Hemberger J; Oschmann P
Neuroimmunomodulation; 2009; 16(3):171-6. PubMed ID: 19246939
[TBL] [Abstract][Full Text] [Related]
11. Can we spot the IFNbeta nonresponders?
Sorensen PS
Neurology; 2008 Dec; 71(24):1936-7. PubMed ID: 18971447
[No Abstract] [Full Text] [Related]
12. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
13. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
Lutterotti A; Kuenz B; Gredler V; Khalil M; Ehling R; Gneiss C; Egg R; Deisenhammer F; Berger T; Reindl M
J Neuroimmunol; 2006 Dec; 181(1-2):145-9. PubMed ID: 17046070
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains.
Arduini RM; Strauch KL; Runkel LA; Carlson MM; Hronowski X; Foley SF; Young CN; Cheng W; Hochman PS; Baker DP
Protein Sci; 1999 Sep; 8(9):1867-77. PubMed ID: 10493588
[TBL] [Abstract][Full Text] [Related]
15. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
Bernal F; Elias B; Hartung HP; Kieseier BC
Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
[TBL] [Abstract][Full Text] [Related]
16. Measurement of intracellular cytokines in MS patients treated with beta-interferon and association of a beta-interferon induced exacerbation with increased expression of gamma-interferon by monocytes.
Toh L; Kilpatrick TJ
J Clin Neurosci; 2001 Sep; 8(5):434-6. PubMed ID: 11535012
[TBL] [Abstract][Full Text] [Related]
17. Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1.
Lamken P; Gavutis M; Peters I; Van der Heyden J; Uzé G; Piehler J
J Mol Biol; 2005 Jul; 350(3):476-88. PubMed ID: 15946680
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
[TBL] [Abstract][Full Text] [Related]
19. Altered maturation of circulating dendritic cells in primary progressive MS patients.
López C; Comabella M; Al-zayat H; Tintoré M; Montalban X
J Neuroimmunol; 2006 Jun; 175(1-2):183-91. PubMed ID: 16698091
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.
Comabella M; Craig DW; Morcillo-Suárez C; Río J; Navarro A; Fernández M; Martin R; Montalban X
Arch Neurol; 2009 Aug; 66(8):972-8. PubMed ID: 19667218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
